Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
navitoclax + celecoxib
- Development stage
- Unknown
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Navitoclax + celecoxib** is a combination of two small-molecule drugs: navitoclax, a potent, orally bioavailable inhibitor of the BCL-2 family of anti-apoptotic proteins (notably BCL-2, BCL-XL, and BCL-W), and celecoxib, a selective COX-2 (cyclooxygenase-2) inhibitor belonging to the nonsteroidal anti-inflammatory drug (NSAID) class. Navitoclax induces apoptosis in cancer cells by mimicking BH3-only proteins and inhibiting pro-survival BCL-2 family proteins. This mechanism is relevant in cancers where these proteins are overexpressed. Celecoxib reduces inflammation and pain by selectively inhibiting COX-2, thereby decreasing prostaglandin synthesis. The specific combination is being studied for its pharmacokinetics, safety, and potential drug-drug interactions, particularly in patients with myeloproliferative neoplasms (such as myelofibrosis), as indicated by a clinical trial that included a dedicated arm evaluating navitoclax's effect on celecoxib PK and safety[1][6]. The combination does not have a unique marketed brand name or regulatory approval as a fixed-dose combination, and is used currently only in clinical research.
- Brand names
- Celebrex (for celecoxib)
- Other names
- navitoclax + celecoxib
02
Targets
Bcl-w (B-cell lymphoma 2-like 2)BCL2L1 (B-cell lymphoma-extra large protein)
Beyond the preview
Go deeper on navitoclax + celecoxib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on navitoclax + celecoxib.